Vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike and accessory proteins ORF7a and ORF8
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1671738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Annika Roth und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Chemistry, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Cathelicidins, SARS-CoV-2, Vitamin D. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The role of vitamin D in Coronavirus Disease 2019 (COVID-19) outcomes remains debated, but emerging evidence suggests it may enhance recovery by strengthening immune responses. Vitamin D upregulates LL-37, an antimicrobial peptide with broad antiviral activity, including potential benefits against SARS-CoV-2. LL-37’s interactions with viral proteins, however, remain incompletely understood.
Methods
We investigated LL-37’s interactions with the SARS-CoV-2 Spike glycoprotein and the accessory proteins ORF7a and ORF8 using surface plasmon resonance and negative-stain electron microscopy. These approaches were employed to assess LL-37’s binding capabilities and potential impact on viral infectivity.
Results
LL-37 bound multiple domains of the Spike protein and inhibited its interaction with the human angiotensin-converting enzyme 2 (hACE2) receptor in vitro . Up to seven LL-37 molecules were observed surrounding Spike, forming a halo-like structure that may block receptor engagement. LL-37 also bound to ORF7a and ORF8, potentially impairing their ability to disrupt host cell processes. Notably, LL-37’s interaction with ORF7a may prevent degradation of SNAP29, restoring autophagy and promoting viral clearance.
Conclusions
LL-37 disrupts key viral-host interactions by binding to Spike, ORF7a, and ORF8, thereby reducing SARS-CoV-2 infectivity. These findings highlight LL-37’s potential as a therapeutic agent in COVID-19 and provide mechanistic insight into its antiviral actions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Clinical Chemistry, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department of Pediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Center for Biochemistry, Medical Faculty and University Hospital Cologne, Cologne, Germany.
- Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden.
- Colzyx AB, Lund, Sweden.
- Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Zitieren
APA
Roth, A., Lütke, S., Mörgelin, M., Meinberger, D., Hermes, G., Sengle, G., Koch, M., Drexelius, M., Gebauer, J., Neundorf, I., Elezagic, D., Paulsson, M., Streichert, T., & Klatt, A. R. (2025). Vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike and accessory proteins ORF7a and ORF8. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1671738
Vancouver
Roth A, Lütke S, Mörgelin M, Meinberger D, Hermes G, Sengle G, et al. Vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike and accessory proteins ORF7a and ORF8. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1671738
BibTeX
@article{Roth2025,
author = {Roth, Annika and Lütke, Steffen and Mörgelin, Matthias and Meinberger, Denise and Hermes, Gabriele and Sengle, Gerhard and Koch, Manuel and Drexelius, Marco and Gebauer, Jan and Neundorf, Ines and Elezagic, Dzemal and Paulsson, Mats and Streichert, Thomas and Klatt, Andreas R},
title = {Vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike and accessory proteins ORF7a and ORF8},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1671738}
}
EUVIMED